Association strongest for B-cell precursor acute lymphoblastic leukemia
THURSDAY, March 28, 2024 (HealthDay News) — Exclusive breastfeeding duration of at least three months may decrease the risk for childhood hematologic cancers, according to a study published online March 26 in JAMA Network Open.
Signe Holst Søegaard, Ph.D., from the Danish Cancer Society in Copenhagen, and colleagues investigated whether longer duration of exclusive breastfeeding is associated with a decreased risk for childhood acute lymphoblastic leukemia (ALL) and other childhood cancers. The analysis included administrative data for 309,473 children born between January 2005 and December 2018, identified from the Danish National Child Health Register.
The researchers found that compared with exclusive breastfeeding duration of less than three months, exclusive breastfeeding for at least three months was associated with a decreased risk for hematologic cancers (adjusted hazard ratio [aHR], 0.66; 95 percent confidence interval [CI], 0.46 to 0.95), which was largely attributable to a decreased risk for B-cell precursor ALL (BCP-ALL; aHR, 0.62; 95 percent CI, 0.39 to 0.99). There were no associations between breastfeeding duration and risk for central nervous system tumors (aHR, 0.96; 95 percent CI, 0.51 to 1.88) or solid tumors (aHR, 0.87; 95 percent CI, 0.55 to 1.41).
“This finding is consistent with emerging investigations implicating early gut microbiome maturation in childhood BCP-ALL pathogenesis,” the authors write. “To inform future preemptive interventions, additional studies should investigate the biologic mechanisms underlying the observed association.”
Nonmedical Expense Reimbursement May Make Cancer Trials More Accessible
Genetic Screening Can ID Hemoglobinopathy Prevalence
Obesity Linked to Early-Onset Cancer Risk in Young Adults
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions